Did you mean cerlapirdine of pf 5212365 of sar 551 of セルラピリジン?
Displaying drugs 101 - 125 of 183 in total
PF-00610355
PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
Investigational
Matched Name: … PF-00610355 …
Matched Description: … PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease …
Matched Description: … PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease …
PF-04691502
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Investigational
Matched Name: … PF-04691502 …
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
PF-03635659
Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational
Matched Name: … PF-03635659 …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Name: … PF-05241328 …
Matched Description: … PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics ( …
Matched Description: … PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics ( …
PF-07304814
PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects . PF-07304814, developed by Pfizer, was first identified during the...
Investigational
Matched Name: … PF-07304814 …
Matched Description: … PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) ... Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its ... PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was …
Matched Description: … PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) ... Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its ... PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was …
PF-06305591
Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).
Investigational
Matched Name: … PF-06305591 …
Matched Description: … Doses of PF-06305591). ... Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple …
Matched Description: … Doses of PF-06305591). ... Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple …
PF-04457845
PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
Investigational
Matched Name: … PF-04457845 …
Matched Description: … PF-04457845 is under investigation in Fear Conditioning. ... PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence. …
Matched Description: … PF-04457845 is under investigation in Fear Conditioning. ... PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence. …
PF-05180999
PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).
Investigational
Matched Name: … PF-05180999 …
Matched Description: … of a Modified-Release Formulation of PF-05180999). ... PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability …
Matched Description: … of a Modified-Release Formulation of PF-05180999). ... PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability …
PF-06291874
PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Name: … PF-06291874 …
Matched Description: … PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics ... And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus …
Matched Description: … PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics ... And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus …
PF-06260414
PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects).
Investigational
Matched Name: … PF-06260414 …
Matched Description: … PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability ... Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects …
Matched Description: … PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability ... Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects …
PF-05230907
PF-05230907 is a recombinant activated Factor X variant.
Investigational
Matched Name: … PF-05230907 …
Matched Description: … PF-05230907 is a recombinant activated Factor X variant. …
Matched Description: … PF-05230907 is a recombinant activated Factor X variant. …
PF-4191834
PF-4191834 has been investigated for the basic science of Asthma.
Investigational
Matched Name: … PF-4191834 …
Matched Description: … PF-4191834 has been investigated for the basic science of Asthma. …
Matched Description: … PF-4191834 has been investigated for the basic science of Asthma. …
PF-07799933
PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.
Investigational
Matched Name: … PF-07799933 …
Matched Description: … PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer. …
Matched Description: … PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer. …
PF-00217830
PF-00217830 has been used in trials studying the treatment of Schizophrenia.
Investigational
Matched Name: … PF-00217830 …
Matched Description: … PF-00217830 has been used in trials studying the treatment of Schizophrenia. …
Matched Description: … PF-00217830 has been used in trials studying the treatment of Schizophrenia. …
PF-06273340
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
Investigational
Matched Name: … PF-06273340 …
Matched Description: … Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration ... and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of …
Matched Description: … Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration ... and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of …
PF-06815345
PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in Healthy Subjects).
Investigational
Matched Name: … PF-06815345 …
Matched Description: … PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in …
Matched Description: … PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in …
PF-5190457
PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).
Investigational
Matched Name: … PF-5190457 …
Matched Description: … PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations …
Matched Description: … PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations …
PF-05105679
PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).
Investigational
Matched Name: … PF-05105679 …
Matched Description: … Volunteers Study Of PF-05105679). ... PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy …
Matched Description: … Volunteers Study Of PF-05105679). ... PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy …
Pf-04531083
Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain.
Investigational
Matched Name: … Pf-04531083 …
Matched Description: … Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain. …
Matched Description: … Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain. …
PF-06700841
PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).
Investigational
Matched Name: … PF-06700841 …
Matched Description: … PF-06700841 in Japanese Healthy Volunteers). ... PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of …
Matched Description: … PF-06700841 in Japanese Healthy Volunteers). ... PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of …
PF-04620110
PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Investigational
Matched Name: … PF-04620110 …
Matched Description: … In Healthy Overweight Or Obese Subjects). ... PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 …
Matched Description: … In Healthy Overweight Or Obese Subjects). ... PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 …
PF-03654764
PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis.
Investigational
Matched Name: … PF-03654764 …
Matched Description: … PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis. …
Matched Description: … PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis. …
PF-04991532
PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Glucose Metabolism Disorders.
Investigational
Matched Name: … PF-04991532 …
Matched Description: … PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes …
Matched Description: … PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes …
PF-03463275
PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.
Investigational
Matched Name: … PF-03463275 …
Matched Description: … PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments …
Matched Description: … PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments …
Displaying drugs 101 - 125 of 183 in total